DNA vaccine aims to train body to fight breast cancer
NCT ID NCT02204098
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether a DNA vaccine that targets a protein called mammaglobin-A (found on many breast cancer cells) is safe for people with ER+, HER2- breast cancer. The vaccine is given alongside standard hormone therapy or chemotherapy before surgery. The study involves 27 participants and focuses on safety and whether the vaccine sparks an immune response against cancer cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Phone-Based navigation could boost breast cancer detection in kenya
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple